Seven Grand Managers LLC Purchases 395,095 Shares of Caris Life Sciences, Inc. $CAI

Seven Grand Managers LLC increased its position in Caris Life Sciences, Inc. (NASDAQ:CAI) by 395.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 495,095 shares of the company’s stock after acquiring an additional 395,095 shares during the quarter. Caris Life Sciences comprises about 1.0% of Seven Grand Managers LLC’s holdings, making the stock its 28th biggest holding. Seven Grand Managers LLC owned 0.18% of Caris Life Sciences worth $13,358,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. UBS Group AG boosted its position in shares of Caris Life Sciences by 825.9% in the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock valued at $58,924,000 after acquiring an additional 1,948,107 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $3,942,000. Zevenbergen Capital Investments LLC bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $14,655,000. Hamilton Lane Advisors LLC bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $1,584,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $2,498,000.

Analyst Ratings Changes

CAI has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. BTIG Research dropped their target price on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Canaccord Genuity Group dropped their target price on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Friday, March 13th. The Goldman Sachs Group initiated coverage on shares of Caris Life Sciences in a research report on Wednesday, April 1st. They set a “buy” rating and a $27.00 target price for the company. Finally, New Street Research initiated coverage on shares of Caris Life Sciences in a research report on Friday, May 8th. They set a “market perform” rating for the company. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $27.56.

Caris Life Sciences Stock Performance

Shares of CAI opened at $15.38 on Thursday. The company has a market cap of $4.35 billion and a price-to-earnings ratio of -2.02. The company has a current ratio of 7.05, a quick ratio of 6.52 and a debt-to-equity ratio of 0.64. Caris Life Sciences, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $42.50. The business has a 50 day simple moving average of $18.16.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. Caris Life Sciences had a net margin of 3.75% and a return on equity of 98.28%. The business’s quarterly revenue was up 125.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.73) EPS. As a group, equities research analysts predict that Caris Life Sciences, Inc. will post 0.1 earnings per share for the current year.

Insider Buying and Selling at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca acquired 31,050 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the acquisition, the director owned 49,671 shares in the company, valued at $802,186.65. The trade was a 166.75% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 7.80% of the company’s stock.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.